These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38048735)

  • 1. FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1.
    Guo C; Zhou N; Lu Y; Mu M; Li Z; Zhang X; Tu L; Du J; Li X; Huang D; Xu Q; Zheng X
    Biomed Pharmacother; 2024 Jan; 170():115955. PubMed ID: 38048735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
    Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L
    J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4.
    Chen J; Du F; Dang Y; Li X; Qian M; Feng W; Qiao C; Fan D; Nie Y; Wu K; Xia L
    Hepatology; 2020 May; 71(5):1712-1731. PubMed ID: 31529503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
    Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
    J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.
    Miura S; Mitsuhashi N; Shimizu H; Kimura F; Yoshidome H; Otsuka M; Kato A; Shida T; Okamura D; Miyazaki M
    BMC Cancer; 2012 Feb; 12():56. PubMed ID: 22309595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma.
    Li Y; Zhang W; Doughtie A; Cui G; Li X; Pandit H; Yang Y; Li S; Martin R
    Oncotarget; 2016 Aug; 7(32):52329-52339. PubMed ID: 27447573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.
    Zhao H; Lv F; Liang G; Huang X; Wu G; Zhang W; Yu L; Shi L; Teng Y
    Oncotarget; 2016 Mar; 7(12):13575-86. PubMed ID: 26498355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer.
    Hu L; Cong L
    Oncol Rep; 2015 Nov; 34(5):2683-91. PubMed ID: 26323668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
    Gao L; Shay C; Lv F; Wang X; Teng Y
    Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF19-
    Raja A; Park I; Haq F; Ahn SM
    Cells; 2019 Jun; 8(6):. PubMed ID: 31167419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma.
    Tao Z; Cui Y; Xu X; Han T
    Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2208844119. PubMed ID: 36179047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4-GSK3β-Nrf2 Signaling.
    Teng Y; Zhao H; Gao L; Zhang W; Shull AY; Shay C
    Cancer Res; 2017 Nov; 77(22):6215-6225. PubMed ID: 28951455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
    Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
    Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver.
    Cui G; Martin RC; Jin H; Liu X; Pandit H; Zhao H; Cai L; Zhang P; Li W; Li Y
    J Exp Clin Cancer Res; 2018 Jul; 37(1):136. PubMed ID: 29973237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.
    Kanzaki H; Chiba T; Ao J; Koroki K; Kanayama K; Maruta S; Maeda T; Kusakabe Y; Kobayashi K; Kanogawa N; Kiyono S; Nakamura M; Kondo T; Saito T; Nakagawa R; Ogasawara S; Suzuki E; Ooka Y; Muroyama R; Nakamoto S; Yasui S; Tawada A; Arai M; Kanda T; Maruyama H; Mimura N; Kato J; Zen Y; Ohtsuka M; Iwama A; Kato N
    Sci Rep; 2021 Mar; 11(1):5303. PubMed ID: 33674622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential.
    Xie H; Alem Glison DM; Kim RD
    Expert Opin Investig Drugs; 2022 Apr; 31(4):393-400. PubMed ID: 34913780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation.
    He Q; Huang W; Liu D; Zhang T; Wang Y; Ji X; Xie M; Sun M; Tian D; Liu M; Xia L
    Theranostics; 2021; 11(12):5759-5777. PubMed ID: 33897880
    [No Abstract]   [Full Text] [Related]  

  • 18. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.
    Tiong KH; Tan BS; Choo HL; Chung FF; Hii LW; Tan SH; Khor NT; Wong SF; See SJ; Tan YF; Rosli R; Cheong SK; Leong CO
    Oncotarget; 2016 Sep; 7(36):57633-57650. PubMed ID: 27192118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
    Mellor HR
    Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma.
    Lin ZZ; Hsu C; Jeng YM; Hu FC; Pan HW; Wu YM; Hsu HC; Hu MC; Cheng AL
    Liver Int; 2019 Sep; 39(9):1682-1691. PubMed ID: 30698907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.